AI Networking Cookbook: Practical recipes for AI-assisted network automation and development
TL;DR
Combined in silico and experimental findings highlight hesperidin’s strong binding to key molecular targets, whereas experimental evidence also confirms its antioxidant, anti-inflammatory, and anti-apoptotic effects, supporting its potential as a disease-modifying candidate in PD therapy.
A narrative review evaluates the therapeutic potential of semaglutide in PD, focusing on its molecular mechanisms and preclinical and emerging clinical evidence, and suggests that semaglutide crosses the blood-brain barrier and activates GLP-1 receptors in neuronal and glial cells, reducing microglial activation, neuroinflammation, and oxidative stress while improving mitochondrial function, cellular metabolism, and neuronal survival.
Overall, saponins represent a promising avenue for the development of novel neuroprotective and disease-modifying therapies for PD, and challenges such as poor bioavailability in natural sources and limited access to brain remain significant barriers to clinical translation.
NAR has demonstrated the ability to reduce amyloid-β plaque deposition, inhibit α-synuclein aggregation, preserve dopaminergic neurons, modulate immune responses in multiple sclerosis, and improve functional recovery after spinal cord injury.
Parkinson's disease (PD) remains a neurodegenerative disorder without effective disease-modifying therapies, largely due to its multifactorial pathogenesis. We report that the natural flavonoid Astragalin (AST) concurrently addresses three core pathological processes in PD, namely dopaminergic neuron degeneration, α-synucleinopathy, and neuroinflammation, through coordinated modulation of interconnected molecular pathways. In both subacute MPTP- and chronic rotenone-induced murine PD models, AST preserved 85% of nigral tyrosine hydroxylase-positive neurons, fully prevented motor deficits, and suppressed phosphorylated α-synuclein (α-Syn) accumulation and Lewy body-like inclusion formation. Mechanistically, AST activated the BDNF-TrkB/AKT pro-survival pathway, enhanced NRF2-mediated antioxidant defense, and suppressed neuroinflammatory cascades by dual inhibition of Notch1/HES-1 and COP1-C/EBPβ signaling, leading to attenuated microglial and astrocytic activation. These findings position AST as a promising multi-target therapeutic neuroprotective candidate with disease-modifying potential, providing a structural scaffold for developing combination-inspired anti-PD strategies.
Neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and cerebral ischemia, represent an escalating global health crisis with limited effective therapies. The multifactorial pathogenesis of these disorders, encompassing protein aggregation, oxidative stress, neuroinflammation, and mitochondrial dysfunction, necessitates therapeutic approaches that target multiple pathways. Plant secondary metabolites have emerged as promising neuroprotective agents, offering multi-targeted mechanisms and favorable safety profiles. This review comprehensively examines the neuropharmacology of key secondary metabolites, including huperzine A, curcumin, resveratrol, epigallocatechin gallate (EGCG), and ginsenosides, focusing on their mechanisms against neurodegeneration. We critically evaluate evidence for neuroprotection through acetylcholinesterase inhibition, antioxidant and anti-inflammatory effects, mitochondrial protection, and modulation of protein aggregation pathways. Furthermore, we assess the therapeutic potential of these compounds in Alzheimer's disease, Parkinson's disease, and cerebral ischemia, evaluating preclinical and clinical evidence. Polyphenols, including curcumin and resveratrol, exert significant inhibitory effects on the NF-κB pathway, making them promising candidates for treating neurological disorders. Despite promising findings, challenges including bioavailability, blood-brain barrier penetration, and clinical translation persist. This review identifies research gaps and discusses emerging strategies for optimizing neuroprotective natural products for clinical application.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.